Neogenix Receives Orphan Drug Status for Pancreatic Cancer Treatment

Neogenix announced Monday that the U.S. Food and Drug Administration has granted orphan drug designation to the company’s product candidate ensituximab (monoclonal antibody NPC-1C) for the treatment of pancreatic cancer.
ADVFN